A clinical trial of dextromethorphan in amyotrophic lateral sclerosis

Acta Neurologica Scandinavica

Volumn 96, Issue 1, 1997, Pages 8-13

  Gredal, O ^a,b   Werdelin, L ^c,d   Bak, S ^e   Christensen, P B ^f   Boysen, G ^d,g   Kristensen, M O ^g   Jespersen, J H ^f   Regeur, L ^c   Hinge, H H ^b   Jensen, T S ^f  

^a Sct Hans Hospital   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g Rigshospitalet   (Denmark)

Author keywords

Amyotrophic lateral sclerosis; Clinical trial; Dextromethophan; Disease progression; Double blind method; Glutamate antagonist; Placebo; Survival

Indexed keywords

DEXTROMETHORPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LUNG FUNCTION; MALE; MOTOR NEURON DISEASE; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

EID: 8544239352     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1997.tb00231.x     Document Type: Article

References (22)

1. PLAITAKIS A, CAROSCIO JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987: 22: 575-9.
2. PERRY TL, KRIEGER C, HANSEN S, EISEN A. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990: 28: 12-17.
3. ROTHSTEIN JD, TSAI G, KUNCL RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990: 28: 18-25.
4. ROTHSTEIN JD, MARTIN LJ, KUNCL RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992: 326: 1464-8.
5. ROTHSTEIN JD, KUNCL RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995: 65: 643-51.
6. ROTHSTEIN JD, VAN KAMMEN M, LEVEY AI, MARTIN LJ, KUNCL RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995: 38: 73-84.
7. BENSIMON G, LACOMBLEZ L, MEININGER V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994: 330: 585-91.
8. EISEN A, STEWART H, SCHULZER M, CAMERON D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993: 20: 297-301.
9. APPELBAUM JS, SALAZAR-GRUESO EF, RICHMAN JG, SHANAHAN M, ROOS RP. Dextromethorphan in the treatment of ALS: a pilot study. Neurology 1991: 41 (Suppl. 1): 393.
10. HOLLANDER D, PRADAS J, KAPLAN R, MCLEOD H, EVANS W, MUNSAT T. Long-term high-dose dextromethorphan in amyotrophic lateral sclerosis. Ann Neurol 1992: 32: 280.
11. ASKMARK H, AQUILONIUS SM, GILLBERG PG, LIEDHOLM LJ, STALBERO E, WUOPIO R. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993: 56: 197-200.
12. TORTELLA FC, PELLICANO M, BOWERY NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989: 10: 501-7.
13. FRANKLIN PH, MURRAY TF. High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. Mol Pharmacol 1992: 41: 134-46.
14. CHURCH J, LODGE D, BERRY SC. Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. Eur J Pharmacol 1985: 111: 185-90.
15. CHOI DW. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 1987: 403: 333-6.
16. CHOI DW, PETERS S, VISESKUL V. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons. J Pharmacol Exp Ther 1987: 242: 713-20.
17. POCOCK SJ, SIMON R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975: 31: 103-15.
18. HILLEL AD, MILLER RM, YORKSTON K, MCDONALD E, NORRIS FH, KONIKOW N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 1989: 8: 142-50.
19. BLIN O, AZULAY JP, DESNUELLE C et al. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 1996: 19: 189-92.
20. HOLLANDER D, PRADAS J, KAPLAN R, MCLEOD HL, EVANS WE, MUNSAT TL. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 1994: 36: 920-4.
21. BEM JL, PECK R. Dextromethorphan. An overview of safety issues. Drug Saf 1992: 7: 190-9.
22. WALKER FO, HUNT VP. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989: 12: 322-30.